EMEA-001995-PIP01-16-M03

Key facts

Invented name
Breyanzi
Active substance
Lisocabtagene maraleucel
Therapeutic area
Oncology
Decision number
P/0558/2021
PIP number
EMEA-001995-PIP01-16-M03
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
  • Treatment of B-lymphoblastic leukaemia/lymphoma
  • Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

E-mail: medical.information@bms.com
Tel: +44 1423 53 3610

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating